​The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.

Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.

The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.

Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week.

Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.

This week, the German drug company announced that it is closing the doors to its 'innovation hub' in Mission Bay.

Has a student, colleague or mentee of yours asked for a recommendation from you? If you’re looking for how to compose one, a template or a sample letter, we’ll teach you how and what to write.

Researchers at the University of Helsinki and the Beatson Institute for Cancer Research in Glasgow have discovered how mutated cells promote their chances to form cancer. Typically, the accumulation of harmful cells is prevented by active competition between multiple stem cells in intestinal glands, called crypts.

People working on business development are the ones responsible for dealing with the business side of the organization. Dealing with a lot of people, clients and a huge team is part of this job.

​The new division would benefit from Hahn's experience and help steer the company's Preemptive Medicine and Health Security initiative.

Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.

A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.

The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.

Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.

Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.

A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.

The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.

Please check out the biopharma industry's COVID-19 stories that are trending for June 15, 2021.

The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).

Brooklyn ImmunoTherapeutics and Novellus have been doing quite a bit of business together lately, including a licensing agreement and co-locating at a research and development center. Now, a potential acquisition can be added to the growing list.